Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study Meeting Abstract
| Authors: | Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Oh, D. Y.; Omori, T.; Moehler, M.; Garrido, M.; Cunha Sousa Oliveira, S.; Liberman, M.; Castro Oliden, V.; Bilici, M.; Kurland, J. F.; Xynos, I.; Mann, H.; Tabernero, J. |
| Abstract Title: | Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1315 |
| End Page: | S1316 |
| Language: | English |
| ACCESSION: | WOS:001087480203560 |
| DOI: | 10.1016/j.annonc.2023.10.074 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA73 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
